Your browser doesn't support javascript.
loading
Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
Miyazato, Yusuke; Yamamoto, Kei; Nakaya, Yuichiro; Morioka, Shinichiro; Takeuchi, Junko S; Takamatsu, Yuki; Maeda, Kenji; Kimura, Moto; Sugiura, Wataru; Mitsuya, Hiroaki; Yano, Masao; Ohmagari, Norio.
Afiliação
  • Miyazato Y; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
  • Yamamoto K; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan. Electronic address: kyamamoto@hosp.ncgm.go.jp.
  • Nakaya Y; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan; Division of Infectious Diseases, Shizuoka Cancer Center Hospital and Research Institute, Shizuoka, 411-8777, Japan.
  • Morioka S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
  • Takeuchi JS; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
  • Takamatsu Y; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, 162-0052, Japan.
  • Maeda K; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, 162-0052, Japan.
  • Kimura M; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
  • Sugiura W; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
  • Mitsuya H; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, 162-0052, Japan.
  • Yano M; Department of Surgery, Minamimachida Hospital, Tokyo, 194-0004, Japan.
  • Ohmagari N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
J Infect Chemother ; 28(7): 991-994, 2022 Jul.
Article em En | MEDLINE | ID: mdl-35337728
Management of COVID-19 patients with humoral immunodeficiency is challenging. We describe a woman with COVID-19 with multiple relapses due to anti-CD20 monoclonal antibody treatment. She was successfully treated with casirivimab/imdevimab and confirmed to have neutralizing antibodies. This case suggests that monoclonal antibodies have therapeutic and prophylactic value in patients with humoral immunodeficiency.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antineoplásicos Imunológicos / Tratamento Farmacológico da COVID-19 Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antineoplásicos Imunológicos / Tratamento Farmacológico da COVID-19 Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article